BR9502072A - Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica - Google Patents

Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica

Info

Publication number
BR9502072A
BR9502072A BR9502072A BR9502072A BR9502072A BR 9502072 A BR9502072 A BR 9502072A BR 9502072 A BR9502072 A BR 9502072A BR 9502072 A BR9502072 A BR 9502072A BR 9502072 A BR9502072 A BR 9502072A
Authority
BR
Brazil
Prior art keywords
pct
treatment
pharmaceutical composition
medical condition
compound method
Prior art date
Application number
BR9502072A
Other languages
English (en)
Inventor
Akemi Ando
Rodney William Stevens
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9502072A publication Critical patent/BR9502072A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR9502072A 1994-05-19 1995-05-18 Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica BR9502072A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12810594A JP3179286B2 (ja) 1994-05-19 1994-05-19 Ｎ−ヒドロキシ尿素系抗炎症剤
CA002223023A CA2223023C (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents
PCT/JP1995/001127 WO1996040659A1 (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents

Publications (1)

Publication Number Publication Date
BR9502072A true BR9502072A (pt) 1996-04-09

Family

ID=27170556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9502072A BR9502072A (pt) 1994-05-19 1995-05-18 Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica

Country Status (19)

Country Link
US (1) US5814648A (pt)
EP (1) EP0832078B1 (pt)
JP (2) JP3179286B2 (pt)
AT (1) ATE185803T1 (pt)
AU (1) AU705505B2 (pt)
BR (1) BR9502072A (pt)
CA (1) CA2223023C (pt)
CZ (1) CZ286331B6 (pt)
DE (1) DE69512940T2 (pt)
DK (1) DK0832078T3 (pt)
ES (1) ES2138211T3 (pt)
FI (1) FI974444A (pt)
GR (1) GR3032301T3 (pt)
HU (1) HUT77950A (pt)
IL (1) IL113706A (pt)
NO (1) NO310288B1 (pt)
NZ (1) NZ287551A (pt)
PL (1) PL179853B1 (pt)
WO (1) WO1996040659A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548419A1 (de) * 1995-12-22 1997-06-26 Bayer Ag Substituierte Thiazoline
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
AU2006228690A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2021214048A1 (en) * 2020-04-20 2021-10-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0819069B2 (ja) * 1990-07-25 1996-02-28 アボツト・ラボラトリーズ リポキシゲナーゼ阻害活性を有するアセチレン誘導体
JP2528741B2 (ja) * 1991-01-09 1996-08-28 ファイザー製薬株式会社 オキサゾ―ル、チアゾ―ルおよびイミダゾ―ル化合物
JPH07100687B2 (ja) * 1991-06-13 1995-11-01 ファイザー製薬株式会社 新規なｎ−ヒドロキシ尿素化合物および組成物
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
EP0693054B1 (en) * 1993-04-07 1998-06-10 Pfizer Inc. Cycloalkylhydroxyureas and their use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
JPH07309849A (ja) 1995-11-28
NO975726D0 (no) 1997-12-05
DE69512940T2 (de) 2000-02-17
MX9709986A (es) 1998-03-29
EP0832078A1 (en) 1998-04-01
JPH10506649A (ja) 1998-06-30
NZ287551A (en) 1999-02-25
AU2629495A (en) 1996-12-30
IL113706A (en) 1999-08-17
PL179853B1 (pl) 2000-11-30
PL324012A1 (en) 1998-04-27
ATE185803T1 (de) 1999-11-15
HUT77950A (hu) 1998-12-28
NO975726L (no) 1998-02-03
CZ286331B6 (cs) 2000-03-15
EP0832078B1 (en) 1999-10-20
IL113706A0 (en) 1995-08-31
DE69512940D1 (de) 1999-11-25
FI974444A (fi) 1998-02-04
ES2138211T3 (es) 2000-01-01
DK0832078T3 (da) 2000-04-25
CA2223023C (en) 2001-07-17
FI974444A0 (fi) 1997-12-05
GR3032301T3 (en) 2000-04-27
WO1996040659A1 (en) 1996-12-19
NO310288B1 (no) 2001-06-18
US5814648A (en) 1998-09-29
CA2223023A1 (en) 1996-12-19
AU705505B2 (en) 1999-05-27
CZ382497A3 (cs) 1999-03-17
JP3179286B2 (ja) 2001-06-25

Similar Documents

Publication Publication Date Title
IL100100A0 (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
MA27157A1 (fr) Methode de traitement d'affections osseuses.

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 12A, 13A, 14A, 15A E 16A ANUIDADE(S).

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 12A, 13A, 14A, 15A E 16A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.